Anakinra or canakinumab (anti-IL-1β monoclonal antibody) reduces EMT of BC cells and the number of tumor cells moving into the circulation, which ultimately reduces the bone metastasis of BC [168]. This evidence concerns the gene IL1B and neoplasm.